ClinicalTrials.gg
CompletedNCT04561128Updated Jul 12, 2022

A Trial of SHR-1819 in Healthy Subjects

A Phase 1 interventional study of SHR-1819 and Placebo in Healthy Volunteers, sponsored by Atridia Pty Ltd.. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-12.

Sponsored by Atridia Pty Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a single center, randomized, double-blind, placebo-controlled, single dose escalation phase 1 study.

Read the detailed description

This is a single center, randomized, double-blind, placebo-controlled, single dose escalation phase 1 study. The objective of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous administered SHR-1819 in healthy subjects.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Atridia Pty Ltd. is the lead sponsor of 36 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to understand the trial procedures and possible adverse events, volunteers to participate in the trial, and provides written .
  • Be able to comply with all the requirements and able to complete the study.
  • Male or female aged between 18 years and 55 years (inclusive) at the date of signed consent form.
  • No abnormalities in medical history, general physical examination, vital signs, and laboratory tests.
  • Men and women of (WOCBP) must agree to take effective methods and have no plan to have a child from signing the consent form to 16 weeks after IP administration.

Exclusion criteria

Exclusion Criteria:

  • Positive virus (HBsAg), virus (HCV-Ab), (HIV-Ab), or QuantiFERON-TB Gold tests at screening;
  • Participation in clinical trials of other drugs or medical devices within 3 months prior to screening (according to the date of signed consent form), or in the follow-up period of a clinical study
  • Severe injuries or surgeries within 6 months before screening or plan to do surgeries during the trial
  • Any other circumstances that, in the investigator's judgment, may increase the risk associated with the subject's participation in and completion of the study or could preclude the evaluation of the subject's response
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    SHR-1819

    Experimental: SHR-1819

    Drug: SHR-1819

  • Placebo comparator
    Placebo

    Placebo comparator: placebo

    Drug: Placebo

Interventions

  • SHR-1819 will be subcutaneously administered with different dose levels

  • DrugPlacebo

    Placebo will be subcutaneously administered with different dose levels

06

What researchers measure

Primary outcomes

  1. Adverse events

    Incidence and severity of adverse events

    Time frame: Start of Treatment to end of study (approximately 13 weeks)

Secondary outcomes

  1. Pharmacokinetics-AUC0-last

    Area under the concentration-time curve from time 0 to last time point after SHR-1819 administration

    Time frame: Start of Treatment to end of study (approximately 13 weeks)

  2. Pharmacokinetics-AUC0-inf

    Area under the concentration-time curve from time 0 to infinity after SHR-1819 administration

    Time frame: Start of Treatment to end of study (approximately 13 weeks)

  3. Pharmacokinetics-Tmax

    Time to Cmax of SHR-1819

    Time frame: Up to 13 weeks

  4. Pharmacokinetics-Cmax

    Maximum observed concentration of SHR-1819

    Time frame: Up to 13 weeks

  5. Pharmacokinetics-CL/F

    Apparent clearance of SHR-1819

    Time frame: Up to 13 weeks

  6. Pharmacokinetics-Vz/F

    Apparent volume of distribution during terminal phase of SHR-1819

    Time frame: Up to 13 weeks

  7. Pharmacokinetics-t1/2

    Terminal elimination half-life of SHR-1819

    Time frame: Up to 13 weeks

  8. Change from baseline to end of treatment for TARC/CCL17

    TARC/CCL17

    Time frame: Up to 13 weeks

  9. Change from baseline to end of treatment for IgE

    IgE

    Time frame: Up to 13 weeks

  10. Immunogenicy of SHR-1819 after administration

    Anti-drug antibody

    Time frame: Up to 13 weeks

07

Study locations

1 site
  • Atridia Pty Limited
    Sydney, New South Wales 2000, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Mar 2022, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2020
First posted
Sep 23, 2020
StartActual
Nov 1, 2020
Primary completionActual
Mar 7, 2022
CompletionActual
Mar 7, 2022
Last update
Jul 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04561128
Lead sponsor
Atridia Pty Ltd.
Responsible party
Sponsor
First posted
Sep 23, 2020
Start date
Nov 1, 2020
Primary completion
Mar 7, 2022
Completion
Mar 7, 2022
Last update
Jul 12, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-1819

Start the discussion